课题基金 / 基金详情

Investigation for the specific cancer immunotherapy using antigens recognized by a human natural antibody and the anti-idiotypic antibodies

Investigation for the specific cancer immunotherapy using antigens recognized by a human natural antibody and the anti-idiotypic antibodies
使用人类天然抗体识别的抗原和抗独特型抗体研究特异性癌症免疫疗法
批准号:
13671215
负责人:
KODA Keiji
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2001
资助国家:
日本
项目状态:
已结题
起止时间:
2001 至 2002

项目摘要

项目成果

KODA Keiji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
SK1 is an IgM human monoclonal antibody which recognizes a widely expressed glycoprotein antigen found on adenocarcinoma tissues. The antigen recognized by SK-1 (AgSK1) has a molecular weight of 42-46 kilodaltons and is strongly expressed on cells with high invasion capacity. We have recently identified a peptide sequence that is recognized by SK1. The antigen consisted of 54 amino acids and carboxyl terminal 20 amino acids were the antigenic epitope of SK1. The RT-PCR to determine the quantity of the AgSK1 in the panel of the human tissues revealed that the quantity of the mRNA level which encoded the AgSK1 was high in colon cancer cell lines and tissues. Whereas there was quite low or even no amount of the mRNA level found in non-epithelial tumor cell lines or in the normal colon mucosa, blood of no-cancer-bearing cases. These findings were consistent with the AgSK1 protein level in several tissues and cell lines determined by immunohistochemistry or Western blotting. We are now constructing a fibroblast cell line that had originally no AgSK1 detected but have expressed high level of AgSK1 by gene transduction. The invasion or motility capacity of the fibroblast and the inhibitory effect of this cell line by SK1 is now under investigation.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
Glassy M, Koda K: "The nature of an ideal therapeutic human antibody"Expert. Opin. Biol. Ther.. 2(1). 1-2 (2002)
Glassy M、Koda K:“理想的治疗性人类抗体的本质”专家。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Koda K, Miyazaki M: "Clinical assessment of monoclonal antibodies for the treatment and diagnosis of colorectal cancers"Nippon Rinsho. 60(3). 539-544 (2002)
Koda K、Miyazaki M:“单克隆抗体治疗和诊断结直肠癌的临床评估”Nippon Rinsho。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
幸田圭史, 他: "大腸癌に対するモノクローナル抗体を用いた診断と治療の現況"日本臨床. 60(3). 539-544 (2002)
Keishi Koda 等:“使用单克隆抗体诊断和治疗结直肠癌的现状”日本临床研究 60(3) (2002)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Keiji Koda, Mark C. Glassy, Michael E. McKnight, Jun Yasutomi, Norio Saito, Michael Dan, and Nobuyuki Nakajima: "Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1"Anticancer Res.. 21(1B). 621-627 (2001)
Keiji Koda、Mark C. Glassy、Michael E. McKnight、Jun Yasutomi、Norio Saito、Michael Dan 和 Nobuyuki Nakajima:“用人单克隆抗体 SK-1 进行复发性结直肠癌的免疫治疗”抗癌研究 21(1B)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
13
    Characterization of clinically useful human monoclonal antibodies against cancers of digestive organ origin.
    • 批准号:
      15591376
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $1.34万
    • 财政年份:
      2003
    • 负责人:
      KODA Keiji
    • 依托单位:
    A Basic Study for Cancer-Specific Immunotherapy using a Human Natural Antibody and its Anti-idiotypic Antibodies.
    国内基金
    肝特异SK1/S1P信号轴介导HSC活化参与酒精性肝炎的分子机制研究
    • 批准号:
      82160121
    • 项目类别:
      地区科学基金项目
    • 资助金额:
      34万元
    • 批准年份:
      2021
    • 负责人:
      楚生辉
    • 依托单位:
    PPARα调控SK1/S1P通路保护肾缺血再灌注损伤的作用和机制研究
    • 批准号:
      81800657
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      20.0万元
    • 批准年份:
      2018
    • 负责人:
      李大伟
    • 依托单位: